M.D. Anderson Cancer Center
To find the recommended dose of the combination of avutometinib, defactinib, and everolimus in patients with endometrial cancer that is recurrent and has abnormal RAS activity. The safety and effects of this combination will also be studied.
Primary Objectives To identify the recommended phase 2 dosing (RP2D) of the combination of avutometinib, defactinib and everolimus in participants with recurrent, RAS pathway mutant endometrial cancer. Secondary Objectives To evaluate the tolerability of the RP2D of avutometinib, defactinib and everolimus including dose limiting toxicities that occur during cycle 1.
Eligibility Criteria 1. Participants must have histologically or cytologically confirmed recurrent RAS mutant endometrial cancer. RAS pathway gene activating mutations include KRAS, NRAS, HRAS, BRAF, MEK1, and MEK2 activating mutations. Any endometrial histology is permitted, including endometrioid, clear cell, mesonephric, and serous. 2. Participants must have received prior immune checkpoint inhibition treatment alone or in combination. 3. Unlimited prior systemic therapies are permitted, including any number of prior MEK inhibitor regimens. 4. Ability to understand and willingness to sign…
Given by PO
Given by PO
Given by PO
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.